These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16166346)

  • 1. Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells.
    Ishimura N; Isomoto H; Bronk SF; Gores GJ
    Am J Physiol Gastrointest Liver Physiol; 2006 Jan; 290(1):G129-36. PubMed ID: 16166346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and antitumor effects of TRAIL in human cholangiocarcinoma.
    Tanaka S; Sugimachi K; Shirabe K; Shimada M; Wands JR
    Hepatology; 2000 Sep; 32(3):523-7. PubMed ID: 10960444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
    Sanlioglu AD; Koksal IT; Karacay B; Baykara M; Luleci G; Sanlioglu S
    Cancer Gene Ther; 2006 Jan; 13(1):21-31. PubMed ID: 16052230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
    Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
    Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
    Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
    Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
    Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PKCdelta protects human breast tumor MCF-7 cells against tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis.
    Zhang J; Liu N; Zhang J; Liu S; Liu Y; Zheng D
    J Cell Biochem; 2005 Oct; 96(3):522-32. PubMed ID: 16114000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.
    Saitou Y; Shiraki K; Fuke H; Inoue T; Miyashita K; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Hum Pathol; 2005 Oct; 36(10):1066-73. PubMed ID: 16226105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-related apoptosis-inducing ligand-mediated activation of mitochondria-associated nuclear factor-kappaB in prostatic carcinoma cell lines.
    Guseva NV; Taghiyev AF; Sturm MT; Rokhlin OW; Cohen MB
    Mol Cancer Res; 2004 Oct; 2(10):574-84. PubMed ID: 15498932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors.
    Wenger T; Mattern J; Penzel R; Gassler N; Haas TL; Sprick MR; Walczak H; Krammer PH; Debatin KM; Herr I
    Cell Death Differ; 2006 Oct; 13(10):1740-51. PubMed ID: 16470224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions.
    Begue B; Wajant H; Bambou JC; Dubuquoy L; Siegmund D; Beaulieu JF; Canioni D; Berrebi D; Brousse N; Desreumaux P; Schmitz J; Lentze MJ; Goulet O; Cerf-Bensussan N; Ruemmele FM
    Gastroenterology; 2006 Jun; 130(7):1962-74. PubMed ID: 16762619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4.
    Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J
    Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells.
    Braeuer SJ; Büneker C; Mohr A; Zwacka RM
    Mol Cancer Res; 2006 Oct; 4(10):715-28. PubMed ID: 17050666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
    Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of flow cytometry to molecular medicine: detection of tumor necrosis factor-related apoptosis-inducing ligand receptors in acute myeloid leukaemia blasts.
    Cappellini A; Mantovani I; Tazzari PL; Grafone T; Martinelli G; Cocco L; Martelli AM
    Int J Mol Med; 2005 Dec; 16(6):1041-8. PubMed ID: 16273284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
    van der Sloot AM; Tur V; Szegezdi E; Mullally MM; Cool RH; Samali A; Serrano L; Quax WJ
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8634-9. PubMed ID: 16731632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer gene therapy using a novel secretable trimeric TRAIL.
    Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW
    Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway.
    Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y
    Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.